Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Humacyte Inc shares valued at $9,999 were purchased by Scheessele William John on Apr 14 ’25. At $1.54 per share, Scheessele William John acquired 6,493 shares. The insider’s holdings grew to 22,018 shares worth approximately $57907.34 following the completion of this transaction.
Also, Sander Dale A. purchased 20,000 shares, netting a total of over 30,600 in proceeds. Following the buying of shares at $1.53 each, the insider now holds 40,600 shares.
Before that, Parikh Shamik J had added 7,500 shares to its account. In a trade valued at $11,625, the Chief Medical Officer bought Humacyte Inc shares for $1.55 each. Upon closing the transaction, the insider’s holdings increased to 7,500 shares, worth approximately $19725.0.
Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid December. As of December 11, 2023, H.C. Wainwright has initiated its “Buy” rating for HUMA. Earlier on August 14, 2023, Piper Sandler upgraded its rating. Their new recommendation was “a Neutral” for HUMA stock which previously was a “an Underweight”.
Analyzing HUMA Stock Performance
During the last five days, there has been a surge of approximately 5.62%. Over the course of the year, Humacyte Inc shares have dropped approximately -47.92%. Shares of the company reached a 52-week high of $5.48 on 01/02/25 and a 52-week low of $1.15 on 04/08/25.
Support And Resistance Levels for Humacyte Inc (HUMA)
According to the 24-hour chart, there is a support level at 2.46, which, if violated, would cause prices to drop to 2.28. In the upper region, resistance lies at 2.76. The next price resistance is at 2.89. RSI (Relative Strength Index) is 71.86 on the 14-day chart, showing overbought technical sentiment.
